Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaji Kumar

Showing results (271-280 of 516) with videos related to

Pageof 52
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|August 8, 2024
Comparison of Laboratory Data at Initial Diagnosis of Multiple Myeloma Between Black Africans, African Americans and White patientsLambert A Essiaw, Abiola Bolarinwa, Hongwei Tang, et al.
Blood|May 22, 2012
Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experienceAnita D'Souza, Martha Lacy, Morie Gertz, et al.
Oncogene|June 9, 2005
Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathwayKenji Ishitsuka, Teru Hideshima, Makoto Hamasaki, et al.
Cancer Medicine|June 22, 2018
ARNT/HIF-1β links high-risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myelomaChuan Wu, Ting Yang, Yingmin Liu, et al.
Mayo Clinic Proceedings|January 17, 2003
Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myelomaShaji Kumar, Morie A Gertz, Angela Dispenzieri, et al.
American Journal of Hematology|November 15, 2011
Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosisMaria V Irazabal, Alfonso Eirin, Morie A Gertz, et al.
Blood|September 25, 2024
Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysisRahul Banerjee, Rachael Sexton, Andrew J Cowan, et al.
American Journal of Hematology|August 24, 2010
Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myelomaKristen Detweiler-Short, Suzanne Hayman, Morie A Gertz, et al.
American Journal of Hematology|February 13, 2021
Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapyKitsada Wudhikarn, Leslie Padrnos, Terra Lasho, et al.
American Journal of Cancer Research|July 12, 2021
A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myelomaRobert F Cornell, Michael R Bishop, Shaji Kumar, et al.
Pageof 52

Showing results (271-280 of 516) with videos related to

Sort By:
Pageof 52
Clinical Lymphoma, Myeloma & Leukemia|August 8, 2024
Comparison of Laboratory Data at Initial Diagnosis of Multiple Myeloma Between Black Africans, African Americans and White patientsLambert A Essiaw, Abiola Bolarinwa, Hongwei Tang, et al.
Blood|May 22, 2012
Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experienceAnita D'Souza, Martha Lacy, Morie Gertz, et al.
Oncogene|June 9, 2005
Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathwayKenji Ishitsuka, Teru Hideshima, Makoto Hamasaki, et al.
Cancer Medicine|June 22, 2018
ARNT/HIF-1β links high-risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myelomaChuan Wu, Ting Yang, Yingmin Liu, et al.
Mayo Clinic Proceedings|January 17, 2003
Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myelomaShaji Kumar, Morie A Gertz, Angela Dispenzieri, et al.
American Journal of Hematology|November 15, 2011
Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosisMaria V Irazabal, Alfonso Eirin, Morie A Gertz, et al.
Blood|September 25, 2024
Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysisRahul Banerjee, Rachael Sexton, Andrew J Cowan, et al.
American Journal of Hematology|August 24, 2010
Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myelomaKristen Detweiler-Short, Suzanne Hayman, Morie A Gertz, et al.
American Journal of Hematology|February 13, 2021
Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapyKitsada Wudhikarn, Leslie Padrnos, Terra Lasho, et al.
American Journal of Cancer Research|July 12, 2021
A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myelomaRobert F Cornell, Michael R Bishop, Shaji Kumar, et al.
Pageof 52